Physician profile
Thomas K Koithan
NPI 1235194143
$8,613.15
in general payments reported to CMS, 2019-2025
27 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $319 · 2021: $596 · 2022: $589 · 2023: $3,318 · 2024: $2,963 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,325 · Travel and Lodging: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,324.86 |
| Travel and Lodging | $1,598.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $2,927.96 | 2023 | Neurostar Tms Therapy System |
| Brainsway USA INC | $2,467.40 | 2022-2024 | Brainsway Deep Tms System |
| Abbvie INC. | $711.45 | 2021-2025 | |
| Neos Therapeutics, LP | $585.80 | 2020-2025 | Adzenys Xr-Odt, Exxua |
| Allergan, INC. | $295.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $267.19 | 2021-2025 | Rexulti |
| Almatica Pharma LLC | $152.88 | 2021-2023 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $151.12 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $147.55 | 2022-2024 | |
| Lundbeck LLC | $124.59 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.62 | 2022-2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $112.24 | 2021 | |
| Janssen Pharmaceuticals, INC | $98.76 | 2021-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $79.52 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $65.73 | 2022-2023 | Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $37.63 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $36.54 | 2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $36.14 | 2022 | |
| Sunovion Pharmaceuticals INC. | $29.77 | 2019-2021 | |
| Tris Pharma INC | $29.45 | 2023-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $27.49 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $24.84 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.82 | 2025 | Rejoyn |
| Alkermes, INC. | $21.77 | 2021 | |
| Corium, LLC | $18.73 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.64 | 2025 | Cobenfy |
| Bausch Health US, LLC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Koithan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.